Cipla faces Customs search by Revenue Intelligence unit over drug classification
- Legal
- Pharmaceuticals

Cipla (NSE: CIPLA) said in a filing on 16 Nov 2026 that the Directorate of Revenue Intelligence, Mumbai zonal unit, searched its Vikhroli office and Bhiwandi depot that day under Section 105 of the Customs Act, 1962. The search concerned the classification or exemption of an imported pharmaceutical finished product.
What the search was about
The search was initiated under Section 105 of the Customs Act, 1962, and was carried out and concluded on 16 Nov 2026. The Directorate of Revenue Intelligence, Mumbai zonal unit, searched the company's office in Vikhroli, Mumbai, Maharashtra, and its depot in Bhiwandi, Thane, Maharashtra.
The matter relates to how an imported pharmaceutical finished product is classified for customs purposes, and whether an exemption applies to it. The company says it extended its full co-operation and assistance during the search.
The company's assessment of impact
The company is a large listed drugmaker, with a market value of ₹1,12,655 crore at the 16 Nov 2026 close, and it reported consolidated net profit of ₹851.51 crore for Q2 FY27.
The company's own statement is the only assessment available. The filing does not name the product, and it does not say whether any duty or penalty is involved.
What the search means for Cipla's shareholders
The search is a customs enforcement step at two Maharashtra locations, and the company reports no material effect so far. It is not known whether the matter will lead to a notice, a demand or a further proceeding, and the filing does not say how the classification question will be resolved.
The filing does not give the outcome of the search, the name of the product, or the amount of any duty or penalty. No further dated step is stated.
At a glance
| Item | Detail |
|---|---|
| Authority | Directorate of Revenue Intelligence, Mumbai zonal unit |
| Date of search | 16 Nov 2026 |
| Locations | Vikhroli office, Mumbai; Bhiwandi depot, Thane |
| Legal basis | Section 105 of the Customs Act, 1962 |
| Subject | Classification or exemption of an imported pharmaceutical finished product |
| Company statement | No material impact on financials, operations or other activities |
Filed with NSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.